Arcus Biosciences annual current ratio
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences Current Ratio Growth & History (RCUS)
Arcus Biosciences's current ratio was 4.36 for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 4.36 | −0.14 | −3.03% |
| 2024 | 2024-12-31 | 4.50 | −0.02 | −0.46% |
| 2023 | 2023-12-31 | 4.52 | −1.01 | −18.31% |
| 2022 | 2022-12-31 | 5.53 | −2.07 | −27.28% |
| 2021 | 2021-12-31 | 7.60 | 1.55 | +25.71% |
| 2020 | 2020-12-31 | 6.05 | −2.44 | −28.74% |
| 2019 | 2019-12-31 | 8.49 | −6.80 | −44.50% |
| 2018 | 2018-12-31 | 15.29 | 1.39 | +10.02% |
| 2017 | 2017-12-31 | 13.90 | — | — |
Arcus Biosciences quarterly current ratio
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.82 | −0.69 | −15.24% |
| Q1 2026 | 2026-03-31 | 4.04 | −1.33 | −24.80% |
| Q4 2025 | 2025-12-31 | 4.36 | −0.14 | −3.03% |
| Q3 2025 | 2025-09-30 | 3.65 | −1.60 | −30.43% |
| Q2 2025 | 2025-06-30 | 4.50 | −0.63 | −12.28% |
| Q1 2025 | 2025-03-31 | 5.37 | 0.15 | +2.95% |
| Q4 2024 | 2024-12-31 | 4.50 | −0.02 | −0.46% |
| Q3 2024 | 2024-09-30 | 5.24 | 0.83 | +18.86% |
| Q2 2024 | 2024-06-30 | 5.14 | −0.34 | −6.25% |
| Q1 2024 | 2024-03-31 | 5.22 | −0.45 | −8.02% |
| Q4 2023 | 2023-12-31 | 4.52 | −1.01 | −18.31% |
| Q3 2023 | 2023-09-30 | 4.41 | −1.80 | −29.04% |
| Q2 2023 | 2023-06-30 | 5.48 | −2.01 | −26.80% |
| Q1 2023 | 2023-03-31 | 5.67 | −2.17 | −27.67% |
| Q4 2022 | 2022-12-31 | 5.53 | −2.07 | −27.28% |
| Q3 2022 | 2022-09-30 | 6.21 | 2.40 | +62.83% |
| Q2 2022 | 2022-06-30 | 7.48 | 1.76 | +30.79% |
| Q1 2022 | 2022-03-31 | 7.84 | 1.46 | +22.98% |
| Q4 2021 | 2021-12-31 | 7.60 | 1.55 | +25.71% |
| Q3 2021 | 2021-09-30 | 3.82 | −1.08 | −22.02% |
| Q2 2021 | 2021-06-30 | 5.72 | −6.06 | −51.44% |
| Q1 2021 | 2021-03-31 | 6.38 | −1.54 | −19.44% |
| Q4 2020 | 2020-12-31 | 6.05 | −2.44 | −28.74% |
| Q3 2020 | 2020-09-30 | 4.89 | −4.63 | −48.59% |
| Q2 2020 | 2020-06-30 | 11.78 | 3.19 | +37.17% |
| Q1 2020 | 2020-03-31 | 7.91 | −4.98 | −38.62% |
| Q4 2019 | 2019-12-31 | 8.49 | −6.80 | −44.50% |
| Q3 2019 | 2019-09-30 | 9.52 | −6.45 | −40.38% |
| Q2 2019 | 2019-06-30 | 8.59 | −7.74 | −47.39% |
| Q1 2019 | 2019-03-31 | 12.89 | −6.88 | −34.81% |
| Q4 2018 | 2018-12-31 | 15.29 | 1.39 | +10.02% |
| Q3 2018 | 2018-09-30 | 15.97 | — | — |
| Q2 2018 | 2018-06-30 | 16.33 | — | — |
| Q1 2018 | 2018-03-31 | 19.78 | — | — |
| Q4 2017 | 2017-12-31 | 13.90 | — | — |
Arcus Biosciences current ratio trends
Over the last five fiscal years, Arcus Biosciences's current ratio decreased from 6.05 to 4.36, a change of −1.69. The latest reported quarter, Q2 2026, shows 3.82.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
